title: Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the activity of ifosfamide (isophosphamide) in patients with advanced or recurrent leiomyosarcoma not previously exposed to chemotherapy.
  
  
  METHODS
  This is a phase II groupwide study of the Gynecologic Oncology Group. Thirty-five patients were treated with ifosfamide 1.5 gm/m2 daily intravenously for 5 days with mesna (mercaptoethane sodium sulfonate). Fifty-six patients had received prior abdominal hysterectomy and 15 prior radiotherapy. The dose was reduced to 1.2 gm/m2 daily in patients who had received prior radiotherapy.
  
  
  RESULTS
  Gynecologic Oncology Group grade III or IV granulocytopenia occurred in 4 (11%) patients, and none had grade IV thrombocytopenia. One (2.8%) patient had grade IV neurotoxicity. Partial responses were observed in 6 of 35 (17.2%) patients. The 95% confidence interval for response was 6.6% to 33.7%.
  
  
  CONCLUSIONS
  These results indicate that ifosfamide has modest activity in patients with advanced or recurrent leiomyosarcomas of the uterus.
authors.affiliation: Section of Gynecologic Oncology, Indiana University Medical School.
authors.forename: G P
authors.initials: GP
authors.lastname: Sutton
authors.forename: J A
authors.initials: JA
authors.lastname: Blessing
authors.forename: R J
authors.initials: RJ
authors.lastname: Barrett
authors.forename: R
authors.initials: R
authors.lastname: McGehee
mesh_terms: D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D007890:Leiomyosarcoma / Q000188:drug therapy*; D015080:Mesna / Q000627:therapeutic use*; D008875:Middle Aged; D012074:Remission Induction; D014594:Uterine Neoplasms / Q000188:drug therapy*
chemical_list: D015080:Mesna; D007069:Ifosfamide